triazoles has been researched along with aprepitant in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 1 (25.00) | 2.80 |
Authors | Studies |
---|---|
Elipe, MV; Huskey, SE; Zhu, B | 1 |
Kast, RE | 1 |
Preskorn, SH | 1 |
Alluri, RV; Basu, S; Dodd, S; Emami Riedmaier, A; Huckle, JE; Parrott, N; Pepin, XJH | 1 |
1 review(s) available for triazoles and aprepitant
Article | Year |
---|---|
Glioblastoma: synergy of growth promotion between CCL5 and NK-1R can be thwarted by blocking CCL5 with miraviroc, an FDA approved anti-HIV drug and blocking NK-1R with aprepitant, an FDA approved anti-nausea drug.
Topics: Anti-HIV Agents; Antiemetics; Antineoplastic Agents; Aprepitant; CCR5 Receptor Antagonists; Cyclohexanes; Drug Approval; Drug Interactions; Glioblastoma; Humans; Maraviroc; Mitogen-Activated Protein Kinase 3; Morpholines; Neurokinin-1 Receptor Antagonists; Phosphorylation; Signal Transduction; Triazoles; United States; United States Food and Drug Administration | 2010 |
3 other study(ies) available for triazoles and aprepitant
Article | Year |
---|---|
Application of LC-NMR for the study of the volatile metabolite of MK-0869, a substance P receptor antagonist.
Topics: Animals; Antiemetics; Aprepitant; Chromatography, Liquid; Cytochrome P-450 Enzyme System; Humans; Isoenzymes; Magnetic Resonance Spectroscopy; Microsomes, Liver; Morpholines; Neurokinin-1 Receptor Antagonists; Rats; Rats, Sprague-Dawley; Triazoles | 2003 |
CNS drug development: lessons from the development of ondansetron, aprepitant, ramelteon, varenicline, lorcaserin, and suvorexant. Part I.
Topics: Aprepitant; Azepines; Benzazepines; Central Nervous System Agents; Drug Discovery; History, 20th Century; History, 21st Century; Humans; Indenes; Morpholines; Neurotransmitter Agents; Ondansetron; Quinoxalines; Triazoles; Varenicline | 2014 |
Understanding Mechanisms of Food Effect and Developing Reliable PBPK Models Using a Middle-out Approach.
Topics: Administration, Oral; Aprepitant; Computer Simulation; Drug Liberation; Food-Drug Interactions; Furosemide; Hepatobiliary Elimination; Humans; Intestinal Absorption; Intestinal Elimination; Intestinal Mucosa; Models, Biological; Permeability; Piperazines; Solubility; Triazoles | 2021 |